Latest News - Eli Lilly
Top Corporates Hub
Eli Lilly
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
26.12.2025 04:55
ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement for its Grabody platform, and a USD 15 million equity investment from Eli Lilly and Company ("Lilly").
Novo Nordisk: The Real Comeback Starts Now With The Wegovy Pill
24.12.2025 11:45
Novo Nordisk A/S is rated a Buy with improved execution and valuation gap with LLY to drive outperformance through 2026. Read more on NVO stock here.
Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)
24.12.2025 10:00
Eli Lilly hiked its revenue growth guidance by 7%, while Novo Nordisk was forced to slash its targets by ~12%. See why I'm still bullish on LLY stock.
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy
23.12.2025 06:41
Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
23.12.2025 01:09
The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped overnight.
Why Abivax Stock Was on Fire Today
23.12.2025 00:29
Investors were excited about the possibility of a buyout with a high price tag.
Sector Update: Health Care Stocks Higher in Afternoon Trading
22.12.2025 18:55
Health care stocks advanced Monday afternoon, with the NYSE Health Care Index up 0.5% and the State
Jim Cramer Discusses Major Catalyst For Eli Lilly (LLY)
22.12.2025 17:29
We recently published 8 Stocks on Jim Cramer’s Radar. Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer’s radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry […]
FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers
22.12.2025 16:00
FlyteHealth, a national leader in integrated cardio-kidney-metabolic care, today announced it will provide self-insured organizations with a new access pathway for obesity management medication from Eli Lilly and Company (Lilly) — supported by FlyteHealth's clinically rigorous, outcomes-driven care platform.
Lilly vs Novo Nordisk. Why 2026 Could Redefine the Obesity Drug Market
22.12.2025 14:23
Weight-Loss Drugs Face a 2026 Inflection Point. Here's What Changes Next
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Amid Renewed Tech Confidence
22.12.2025 14:00
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
22.12.2025 14:00
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BofA Maintains Buy on Eli Lilly (LLY), Expects 2027 Earnings to Fully Realize Value of Obesity Drug Launches
22.12.2025 13:42
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy in 2026. On December 15, Bank of America analyst Jason Gerberry lowered the firm’s price target on Eli Lilly to $1,268 from $1,286 with a Buy rating on the shares. BofA remains bullish on Eli Lilly’s stock due to the company’s […]
Eli Lilly and Company (LLY) Announces Updated Meaningful Data on Breast Cancer Treatment
22.12.2025 13:39
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 from $951 while reiterating a Buy rating on the stock. On December 12, Eli Lilly and Company provided updated data […]
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
22.12.2025 13:30
-Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the 100 million cell dose, with the first systemic lupus erythematosus (SLE) patient achieving Definitions of Remission in SLE (DORIS) remission through Month 6- -An additional Phase 1 basket trial has been initiated for zugo-cel in refractory primary immune thrombocytopenic purpura (ITP) and warm autoimmun
Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)
22.12.2025 11:50
Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]
Abivax soars on report of Eli Lilly meeting French officials over possible deal
22.12.2025 09:59
Investing.com -- Abivax shares jumped after fresh media reports revived speculation that U.S. drugmaker Eli Lilly is exploring a takeover of the French biotech company.
Radiopharmaceutical specialist Aktis seeks an IPO
22.12.2025 08:56
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound next year.
2025 Performance Review And Future Strategy
22.12.2025 08:30
Discover top biotech stock picks for 2025 with strong growth potential and overlooked catalysts.